Chiral bioanalytical methods in bioequivalence studies of intravenous vs. oral formulations of ibuprofen
Abstract
According to the Ibuprofen Product‐Specific Bioequivalence Guidance of the European Medicines Agency, achiral bioanalytical methods are considered acceptable for demonstration of bioequivalence of ibuprofen‐containing products.The aim of this investigation is to compare the bioequivalence outcomes obtained with individual R and S ibuprofen enantiomers and the sum of both enantiomers from bioequivalence studies in which new intravenous ibuprofen products were compared with oral ibuprofen products. Bioequivalence was assessed for S and R enantiomers of ibuprofen and the sum of both enantiomers, which was calculated to represent the results that would have been obtained with an achiral assay. The infusion rates of 15, 20, and 30 minutes modify the maximum concentration (Cmax) of the intravenous administrations. In contrast, the time when the maximum concentration is observed (Tmax) was insensitive to detect differences in input rate within this range of infusion times. The eutomer S‐ibuprofen is the least sensitive analyte to detect differences in input rate; therefore, the regulatory acceptance of achiral bioanalytical methods for ibuprofen bioequivalence studies is justified because the sum of both enantiomers is more discriminative than the chiral methods where only the eutomer is used for regulatory decisions.Keywords
This publication has 15 references indexed in Scilit:
- Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studiesEuropean Journal of Clinical Pharmacology, 2010
- Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trialCurrent Therapeutic Research, 2003
- A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental painClinical Therapeutics, 2002
- Comparative Pharmacology of S(+)-Ibuprofen and (RS)-IbuprofenClinical Rheumatology, 2001
- Clinical Pharmacokinetics of IbuprofenClinical Pharmacokinetics, 1998
- Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteersChirality, 1997
- Equipotent inhibition by R(−)−, S(+)‐ and racemic ibuprofen of human polymorphonuclear cell function in vitro.British Journal of Clinical Pharmacology, 1993
- Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugsEuropean Journal of Clinical Pharmacology, 1992
- Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo‐oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)‐ ibuprofen.British Journal of Clinical Pharmacology, 1991
- Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (—)-isomerJournal of Pharmacy and Pharmacology, 1976